Drugs / CD56-CART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03473457 | Apr 2018 → Dec 2020 | acute myeloid leukemia | Zhujiang Hospital | Terminated | No outcome recorded |
| — | NCT03473496 | Mar 2018 → Jan 2020 | plasma cell myeloma | Zhujiang Hospital | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD56-CART | “one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)” NCT03473457 ↗1“one kind of BCMA-CART,CD138-CART,CD56-CART or CD38-CART,subjects will receive 10\^6-10\^7/Kg transduced CAR T cells at one time.” NCT03473496 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor T(CAR-T) Cells Therapy” NCT03473496 ↗ |